Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Adenoviridae Infections 2Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Abdominal Neoplasms 1

Interventions

FS 069 1Doxorubicin 1Cell Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Abdominal Neoplasms × Cell Count × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡